Shares of Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) have been assigned a consensus recommendation of “Hold” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $19.20.

Several research firms have issued reports on AMPH. Piper Jaffray Companies restated a “buy” rating and issued a $19.00 price objective on shares of Amphastar Pharmaceuticals in a research note on Sunday, September 17th. Needham & Company LLC increased their target price on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the stock a “buy” rating in a research note on Friday, December 1st. Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 20th. Jefferies Group set a $19.00 target price on shares of Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, October 29th. Finally, Raymond James Financial downgraded shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 target price for the company. in a research note on Thursday, November 9th.

In related news, Director Michael A. Zasloff sold 63,624 shares of the stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $18.18, for a total transaction of $1,156,684.32. Following the completion of the transaction, the director now directly owns 101,879 shares of the company’s stock, valued at $1,852,160.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO William J. Peters sold 3,026 shares of the stock in a transaction dated Friday, October 13th. The stock was sold at an average price of $18.56, for a total transaction of $56,162.56. The disclosure for this sale can be found here. Insiders have sold 203,440 shares of company stock valued at $3,763,789 in the last quarter. Insiders own 11.10% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Municipal Employees Retirement System of Michigan raised its holdings in Amphastar Pharmaceuticals by 2.8% during the second quarter. Municipal Employees Retirement System of Michigan now owns 8,430 shares of the company’s stock worth $151,000 after purchasing an additional 230 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Amphastar Pharmaceuticals by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 28,701 shares of the company’s stock valued at $512,000 after buying an additional 312 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Amphastar Pharmaceuticals by 17.7% in the second quarter. Victory Capital Management Inc. now owns 5,611 shares of the company’s stock valued at $100,000 after buying an additional 842 shares in the last quarter. Thrivent Financial For Lutherans increased its holdings in Amphastar Pharmaceuticals by 7.2% in the second quarter. Thrivent Financial For Lutherans now owns 21,610 shares of the company’s stock valued at $386,000 after buying an additional 1,460 shares in the last quarter. Finally, Rhumbline Advisers increased its holdings in Amphastar Pharmaceuticals by 2.8% in the second quarter. Rhumbline Advisers now owns 69,763 shares of the company’s stock valued at $1,246,000 after buying an additional 1,925 shares in the last quarter. 44.14% of the stock is owned by hedge funds and other institutional investors.

Amphastar Pharmaceuticals (NASDAQ AMPH) traded down $0.13 during midday trading on Monday, reaching $19.37. 153,200 shares of the company’s stock traded hands, compared to its average volume of 289,282. The company has a quick ratio of 1.86, a current ratio of 3.08 and a debt-to-equity ratio of 0.13. Amphastar Pharmaceuticals has a one year low of $12.05 and a one year high of $20.73. The firm has a market capitalization of $896.53, a P/E ratio of 130.00 and a beta of 1.69.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The company had revenue of $57.90 million during the quarter, compared to the consensus estimate of $57.23 million. During the same quarter in the prior year, the firm posted $0.14 earnings per share. Amphastar Pharmaceuticals’s revenue for the quarter was down 9.8% on a year-over-year basis. sell-side analysts anticipate that Amphastar Pharmaceuticals will post -0.03 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Amphastar Pharmaceuticals Inc (AMPH) Receives Consensus Rating of “Hold” from Analysts” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2017/12/25/amphastar-pharmaceuticals-inc-amph-receives-consensus-rating-of-hold-from-analysts.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Analyst Recommendations for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.